Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $749000.0.

  • Taysha Gene Therapies' Other Accumulated Expenses fell 1449.77% to $749000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $749000.0, marking a year-over-year decrease of 1449.77%. This contributed to the annual value of $752000.0 for FY2024, which is 401.11% up from last year.
  • Per Taysha Gene Therapies' latest filing, its Other Accumulated Expenses stood at $749000.0 for Q3 2025, which was down 1449.77% from $800000.0 recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Other Accumulated Expenses high stood at $1.6 million for Q1 2022, and its period low was $650000.0 during Q4 2022.
  • Its 4-year average for Other Accumulated Expenses is $907533.3, with a median of $777000.0 in 2024.
  • Per our database at Business Quant, Taysha Gene Therapies' Other Accumulated Expenses crashed by 5689.87% in 2023 and then soared by 2863.44% in 2024.
  • Taysha Gene Therapies' Other Accumulated Expenses (Quarter) stood at $650000.0 in 2022, then increased by 11.23% to $723000.0 in 2023, then grew by 4.01% to $752000.0 in 2024, then dropped by 0.4% to $749000.0 in 2025.
  • Its last three reported values are $749000.0 in Q3 2025, $800000.0 for Q2 2025, and $806000.0 during Q1 2025.